ARCHERDX
ArcherDX is advancing molecular pathology with a robust technology platform for genetic mutation detection by next-generation sequencing. By combining proprietary Anchored Multiplexed PCR (AMP™) chemistry in an easy-to-use, lyophilized format and powerful bioinformatics software, the Archer® platform dramatically enhances genetic mutation identification and discovery. ArcherDX provides oncology-focused research products and is pursuing regulatory approval for multiple companion diagnostic assays.
ARCHERDX
Industry:
Biopharma Biotechnology Genetics Life Science Oncology
Founded:
2013-01-01
Address:
Boulder, Colorado, United States
Country:
United States
Website Url:
http://www.archerdx.com
Total Employee:
101+
Status:
Active
Contact:
(877) 771 1093
Email Addresses:
[email protected]
Total Funding:
150 M USD
Technology used in webpage:
Domain Not Resolving SPF Google Maps Amazon HSTS IPv6 Google Google Cloud Microsoft Azure DNS YouTube
Similar Organizations
Allogene Therapeutics
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Aptevo Therapeutics
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market.
Cartesian Therapeutics
Pioneering Potent, Safer Cell Therapy in and Beyond Oncology
Gameto
Gameto is a biotechnology firm focused on female reproductive fertility biotech.
Geron
Geron Corp. operates as a biopharmaceutical company which discovers and develops therapeutic products for cancer. Imetelstat, a novel,
STEMCELL Technologies
STEMCELL Technologies offers scientists a range of products and tools to isolate, culture, and assay cells.
Tessera Therapeutics
Tessera Therapeutics is a biotechnology company that focuses on a new category of genetic medicines.
Tierra Biosciences
Tierra Biosciences is a synthetic biology company that offers an AI-driven platform with a vast range of custom proteins for research.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Current Advisors List
Current Employees Featured
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-01-30 | Baby Genes | Baby Genes acquired by ArcherDX | N/A |
Investors List
Boulder Ventures
Boulder Ventures investment in Series C - ArcherDX
Longwood Fund
Longwood Fund investment in Series C - ArcherDX
ArrowMark Partners
ArrowMark Partners investment in Series C - ArcherDX
PBM Capital Group
PBM Capital Group investment in Series C - ArcherDX
Sands Capital Ventures
Sands Capital Ventures investment in Series C - ArcherDX
Soleus Capital
Soleus Capital investment in Series C - ArcherDX
Perceptive Advisors
Perceptive Advisors investment in Series C - ArcherDX
Driehaus Capital Management
Driehaus Capital Management investment in Series C - ArcherDX
Redmile Group
Redmile Group investment in Series C - ArcherDX
The Peierls Foundation
The Peierls Foundation investment in Series B - ArcherDX
Newest Events participated
Official Site Inspections
http://www.archerdx.com Semrush global rank: 4.87 M Semrush visits lastest month: 1.76 K
- Host name: 177.127.196.35.bc.googleusercontent.com
- IP address: 35.196.127.177
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "ArcherDX"
Democratizing precision oncology - Archer
We are a leading genomic analysis company democratizing precision oncology, providing advanced molecular detection products that are accurate, actionable, easy to use and available worldwide.See details»
Invitae - Invitae and ArcherDX to create a global leader in ...
Jun 22, 2020 The combined company will be poised to transform care for cancer patients, accelerating adoption of genetics through the most comprehensive suite of products and …See details»
ArcherDX - Crunchbase Company Profile & Funding
ArcherDX is a biotechnology firm specializing in cancer research. View contacts for ArcherDX to access new leads and connect with decision-makers. ArcherDX is advancing molecular …See details»
Invitae - Invitae Completes Transaction with ArcherDX to Bring ...
SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to …See details»
Integrated DNA Technologies Acquires ArcherDX Next Generation ...
Invitae to Acquire ArcherDx for Up to $1.4B, in Precision Oncology …
Jun 23, 2020 The combined organization will offer breadth and flexibility in serving customers in more than 95 markets. Precision Oncology “Hub” “ArcherDX and Invitae share a foundational …See details»
The Archer Story - archerdx.com
We are a team of innovative scientists and healthcare experts that envision a world without cancer that is enabled by empowered providers who have access to the right test with highly accurate …See details»
ArcherDX - Funding, Financials, Valuation & Investors - Crunchbase
ArcherDX is a biotechnology firm specializing in cancer research. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. ... How much …See details»
ArcherDX Company Profile - Office Locations, Competitors ... - Craft
ArcherDX addresses the bottlenecks associated with using next-generation sequencing in translational research by offering a robust platform for targeted sequencing applications. By …See details»
ArcherDX Agrees to Combine With Invitae in $1.4 Billion Deal
Colorado – June 23, 2020 – Cooley advised ArcherDX on its agreement to combine with Invitae in a transaction valued at $1.4 billion – creating a genetics leader with unrivaled breadth and …See details»
ArcherDX, Inc. Announces Expansion of Executive Leadership Team …
Sandra Close brings more than 25 years of diverse experience in health outcomes, diagnostic, medical device, and therapy development to ArcherDX, Inc. having successfully guided more …See details»
ArcherDX's Personalized Cancer Monitoring (PCM) Tech Gets FDA ...
Jan 15, 2020 The designation of PCM as a breakthrough device caps a busy week for Boulder, CO-based ArcherDX. Late last week, the company announced it had signed a non-exclusive …See details»
Invitae Completes Transaction with ArcherDX to Bring …
SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to …See details»
ArcherDX and Premier Inc. Partner to Deliver Personalized …
ArcherDX is a leading genomic analysis company democratizing precision oncology through a suite of products and services that are highly accurate, personal, actionable and easy to use in …See details»
Invitae and ArcherDX to create a global leader in comprehensive …
Jun 22, 2020 ArcherDX is a leading genomic analysis company democratizing precision oncology through a suite of products and services that are highly accurate, personal, …See details»
AstraZeneca collaborates with ArcherDX to use personalised …
May 26, 2020 ArcherDX’s personalised assay will be used in AstraZeneca’s recently launched Phase III MERMAID-1 trial to evaluate the effect of adjuvant treatment with Imfinzi …See details»
ArcherDX Blog
For Research Use Only. Not for use in diagnostic procedures. How to contact us. Address. 2477 55th Street, Suite 202. Boulder, CO 80301See details»
ArcherDX and UCL Present New Minimal Residual Disease …
ArcherDX has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a …See details»
Login | ArcherDX
Welcome to the Archer Analysis 7 site. Trouble logging in? The Archer Analysis 7 site was brought online on March 15th, 2022. It requires you to create a new account.See details»
Technology Platform - Archer
Qu, X. et al. Comparison of four next generation sequencing platforms for fusion detection: Oncomine by ThermoFisher, AmpliSeq by illumina, FusionPlex by ArcherDX, and QIAseq by …See details»